Master protocol trials could reimagine the future of rare disease research

A new publication from Kennedy Krieger Institute, University of Rochester Medicine and five other institutions highlights how master protocol trials could revolutionize the future of rare disease research. By employing master protocol trials, researchers could decrease costs, enhance testing efficiency and capacity, and accelerate the delivery of treatments to those with rare diseases.

Patients with rare diseases often lack treatment options, with only 26 out of the FDA-approved 45 drug therapies targeting neurological conditions, accounting for just 4% of all diagnosed neurological disorders. Dr. Erika Augustine, senior author and associate chief science officer at Kennedy Krieger Institute, emphasizes that master protocol trials provide a more efficient and collaborative approach to evaluating potential therapies and bringing effective treatments to patients more rapidly.

Master protocols enable researchers to simultaneously test multiple drugs or conditions using the same clinical framework, unlike traditional trials that require a new framework for each drug or condition. Genetic markers commonly found in multiple rare conditions suggest that targeted gene therapies could lead to master protocol trials offering treatment options for diseases with similar genetic mutations.

The study's authors acknowledge that collaboration is essential to advance rare disease research, as highlighted by Dr. Jennifer Vermilion, director of the University of Rochester Batten Center of Excellence and lead author. Rare diseases, defined as conditions affecting fewer than 200,000 people, are more common than often perceived, with one in ten people diagnosed.

Over 10,000 rare diseases exist, many involving neurological symptoms ranging from body control issues to developmental disabilities. The research was a collaborative effort involving experts from the University of Rochester Medicine, Mass General Brigham, Spaulding Rehabilitation, Harvard Medical School, Berry Consultants, Clinical Trials Transformation Initiative at Duke University, Batten Disease Support, Research, and Advocacy Foundation, Rady Children's Health, UC Irvine, and Kennedy Krieger Institute. The full study is published in the journal Annals of Neurology.